nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—hypothyroidism	0.707	1	CtDrD
Sorafenib—CYP2C8—Levothyroxine—hypothyroidism	0.0214	0.227	CbGbCtD
Sorafenib—CYP2C8—Liotrix—hypothyroidism	0.0209	0.222	CbGbCtD
Sorafenib—ABCB1—Levothyroxine—hypothyroidism	0.0145	0.154	CbGbCtD
Sorafenib—ABCB1—Liothyronine—hypothyroidism	0.0145	0.154	CbGbCtD
Sorafenib—ABCB1—Liotrix—hypothyroidism	0.0142	0.15	CbGbCtD
Sorafenib—CYP3A4—Levothyroxine—hypothyroidism	0.00869	0.0922	CbGbCtD
Sorafenib—Hyperthyroidism—Dextrothyroxine—hypothyroidism	0.00307	0.0507	CcSEcCtD
Sorafenib—Hyperthyroidism—Levothyroxine—hypothyroidism	0.00307	0.0507	CcSEcCtD
Sorafenib—Hyperthyroidism—Liotrix—hypothyroidism	0.00226	0.0373	CcSEcCtD
Sorafenib—Cardiac failure congestive—Liothyronine—hypothyroidism	0.00198	0.0327	CcSEcCtD
Sorafenib—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00136	0.0225	CcSEcCtD
Sorafenib—Myocardial infarction—Liothyronine—hypothyroidism	0.00135	0.0224	CcSEcCtD
Sorafenib—Arrhythmia—Liothyronine—hypothyroidism	0.00111	0.0183	CcSEcCtD
Sorafenib—Hypocalcaemia—Liotrix—hypothyroidism	0.000975	0.0161	CcSEcCtD
Sorafenib—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.000971	0.016	CcSEcCtD
Sorafenib—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.000971	0.016	CcSEcCtD
Sorafenib—Hypertension—Liothyronine—hypothyroidism	0.000932	0.0154	CcSEcCtD
Sorafenib—Cardiac failure—Dextrothyroxine—hypothyroidism	0.000902	0.0149	CcSEcCtD
Sorafenib—Cardiac failure—Levothyroxine—hypothyroidism	0.000902	0.0149	CcSEcCtD
Sorafenib—Mood swings—Dextrothyroxine—hypothyroidism	0.000834	0.0138	CcSEcCtD
Sorafenib—Mood swings—Levothyroxine—hypothyroidism	0.000834	0.0138	CcSEcCtD
Sorafenib—Dehydration—Levothyroxine—hypothyroidism	0.000819	0.0135	CcSEcCtD
Sorafenib—Dehydration—Dextrothyroxine—hypothyroidism	0.000819	0.0135	CcSEcCtD
Sorafenib—Dysphagia—Dextrothyroxine—hypothyroidism	0.000761	0.0126	CcSEcCtD
Sorafenib—Dysphagia—Levothyroxine—hypothyroidism	0.000761	0.0126	CcSEcCtD
Sorafenib—Cardiac failure congestive—Liotrix—hypothyroidism	0.000714	0.0118	CcSEcCtD
Sorafenib—Renal failure acute—Liotrix—hypothyroidism	0.000701	0.0116	CcSEcCtD
Sorafenib—Body temperature increased—Liothyronine—hypothyroidism	0.000697	0.0115	CcSEcCtD
Sorafenib—Weight decreased—Dextrothyroxine—hypothyroidism	0.000688	0.0114	CcSEcCtD
Sorafenib—Weight decreased—Levothyroxine—hypothyroidism	0.000688	0.0114	CcSEcCtD
Sorafenib—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.000669	0.011	CcSEcCtD
Sorafenib—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.000669	0.011	CcSEcCtD
Sorafenib—Myocardial infarction—Levothyroxine—hypothyroidism	0.000665	0.011	CcSEcCtD
Sorafenib—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.000665	0.011	CcSEcCtD
Sorafenib—Cardiac failure—Liotrix—hypothyroidism	0.000664	0.011	CcSEcCtD
Sorafenib—Mood swings—Liotrix—hypothyroidism	0.000614	0.0101	CcSEcCtD
Sorafenib—Dehydration—Liotrix—hypothyroidism	0.000602	0.00995	CcSEcCtD
Sorafenib—Hypokalaemia—Liotrix—hypothyroidism	0.000589	0.00973	CcSEcCtD
Sorafenib—Flushing—Dextrothyroxine—hypothyroidism	0.000565	0.00934	CcSEcCtD
Sorafenib—Flushing—Levothyroxine—hypothyroidism	0.000565	0.00934	CcSEcCtD
Sorafenib—Dysphagia—Liotrix—hypothyroidism	0.00056	0.00924	CcSEcCtD
Sorafenib—Arrhythmia—Levothyroxine—hypothyroidism	0.000544	0.00899	CcSEcCtD
Sorafenib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.000544	0.00899	CcSEcCtD
Sorafenib—Alopecia—Dextrothyroxine—hypothyroidism	0.000538	0.00889	CcSEcCtD
Sorafenib—Alopecia—Levothyroxine—hypothyroidism	0.000538	0.00889	CcSEcCtD
Sorafenib—Weight decreased—Liotrix—hypothyroidism	0.000506	0.00836	CcSEcCtD
Sorafenib—Acute coronary syndrome—Liotrix—hypothyroidism	0.000492	0.00813	CcSEcCtD
Sorafenib—Renal failure—Liotrix—hypothyroidism	0.000491	0.0081	CcSEcCtD
Sorafenib—Myocardial infarction—Liotrix—hypothyroidism	0.000489	0.00808	CcSEcCtD
Sorafenib—Angioedema—Dextrothyroxine—hypothyroidism	0.000484	0.008	CcSEcCtD
Sorafenib—Angioedema—Levothyroxine—hypothyroidism	0.000484	0.008	CcSEcCtD
Sorafenib—Arthralgia—Dextrothyroxine—hypothyroidism	0.000451	0.00746	CcSEcCtD
Sorafenib—Arthralgia—Levothyroxine—hypothyroidism	0.000451	0.00746	CcSEcCtD
Sorafenib—Shock—Levothyroxine—hypothyroidism	0.000426	0.00703	CcSEcCtD
Sorafenib—Shock—Dextrothyroxine—hypothyroidism	0.000426	0.00703	CcSEcCtD
Sorafenib—Flushing—Liotrix—hypothyroidism	0.000416	0.00687	CcSEcCtD
Sorafenib—Arrhythmia—Liotrix—hypothyroidism	0.0004	0.00661	CcSEcCtD
Sorafenib—Alopecia—Liotrix—hypothyroidism	0.000396	0.00654	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.000394	0.00651	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.000394	0.00651	CcSEcCtD
Sorafenib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.000386	0.00637	CcSEcCtD
Sorafenib—Dyspnoea—Levothyroxine—hypothyroidism	0.000386	0.00637	CcSEcCtD
Sorafenib—Dysgeusia—Liotrix—hypothyroidism	0.000382	0.00631	CcSEcCtD
Sorafenib—Fatigue—Levothyroxine—hypothyroidism	0.000373	0.00616	CcSEcCtD
Sorafenib—Fatigue—Dextrothyroxine—hypothyroidism	0.000373	0.00616	CcSEcCtD
Sorafenib—Angioedema—Liotrix—hypothyroidism	0.000356	0.00589	CcSEcCtD
Sorafenib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.000354	0.00584	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.000354	0.00584	CcSEcCtD
Sorafenib—Syncope—Liotrix—hypothyroidism	0.00035	0.00578	CcSEcCtD
Sorafenib—Urticaria—Dextrothyroxine—hypothyroidism	0.000344	0.00568	CcSEcCtD
Sorafenib—Urticaria—Levothyroxine—hypothyroidism	0.000344	0.00568	CcSEcCtD
Sorafenib—Loss of consciousness—Liotrix—hypothyroidism	0.000343	0.00566	CcSEcCtD
Sorafenib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.000342	0.00565	CcSEcCtD
Sorafenib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.000342	0.00565	CcSEcCtD
Sorafenib—Abdominal pain—Levothyroxine—hypothyroidism	0.000342	0.00565	CcSEcCtD
Sorafenib—Body temperature increased—Levothyroxine—hypothyroidism	0.000342	0.00565	CcSEcCtD
Sorafenib—Hypertension—Liotrix—hypothyroidism	0.000337	0.00556	CcSEcCtD
Sorafenib—Arthralgia—Liotrix—hypothyroidism	0.000332	0.00548	CcSEcCtD
Sorafenib—Anaphylactic shock—Liotrix—hypothyroidism	0.000318	0.00526	CcSEcCtD
Sorafenib—Infection—Liotrix—hypothyroidism	0.000316	0.00522	CcSEcCtD
Sorafenib—Shock—Liotrix—hypothyroidism	0.000313	0.00517	CcSEcCtD
Sorafenib—Asthenia—Levothyroxine—hypothyroidism	0.00031	0.00513	CcSEcCtD
Sorafenib—Asthenia—Dextrothyroxine—hypothyroidism	0.00031	0.00513	CcSEcCtD
Sorafenib—Pruritus—Levothyroxine—hypothyroidism	0.000306	0.00506	CcSEcCtD
Sorafenib—Pruritus—Dextrothyroxine—hypothyroidism	0.000306	0.00506	CcSEcCtD
Sorafenib—Anorexia—Liotrix—hypothyroidism	0.000303	0.00501	CcSEcCtD
Sorafenib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000296	0.00489	CcSEcCtD
Sorafenib—Diarrhoea—Levothyroxine—hypothyroidism	0.000296	0.00489	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00029	0.00479	CcSEcCtD
Sorafenib—RAF1—heart—hypothyroidism	0.000284	0.00306	CbGeAlD
Sorafenib—ZAK—liver—hypothyroidism	0.000284	0.00305	CbGeAlD
Sorafenib—Dyspnoea—Liotrix—hypothyroidism	0.000284	0.00469	CcSEcCtD
Sorafenib—EPHX2—female gonad—hypothyroidism	0.000284	0.00305	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—hypothyroidism	0.000284	0.00305	CbGeAlD
Sorafenib—EPHB6—heart—hypothyroidism	0.000283	0.00304	CbGeAlD
Sorafenib—FLT3—female gonad—hypothyroidism	0.000282	0.00303	CbGeAlD
Sorafenib—MKNK1—gonad—hypothyroidism	0.000281	0.00303	CbGeAlD
Sorafenib—MKNK2—pituitary gland—hypothyroidism	0.000278	0.00299	CbGeAlD
Sorafenib—HIPK3—liver—hypothyroidism	0.000278	0.00299	CbGeAlD
Sorafenib—ZAK—cerebellum—hypothyroidism	0.000277	0.00298	CbGeAlD
Sorafenib—Decreased appetite—Liotrix—hypothyroidism	0.000277	0.00457	CcSEcCtD
Sorafenib—Vomiting—Dextrothyroxine—hypothyroidism	0.000275	0.00454	CcSEcCtD
Sorafenib—Vomiting—Levothyroxine—hypothyroidism	0.000275	0.00454	CcSEcCtD
Sorafenib—TIE1—testis—hypothyroidism	0.000275	0.00295	CbGeAlD
Sorafenib—MKNK1—pituitary gland—hypothyroidism	0.000275	0.00295	CbGeAlD
Sorafenib—Fatigue—Liotrix—hypothyroidism	0.000274	0.00453	CcSEcCtD
Sorafenib—FLT4—adrenal gland—hypothyroidism	0.000274	0.00295	CbGeAlD
Sorafenib—FLT4—blood—hypothyroidism	0.000274	0.00295	CbGeAlD
Sorafenib—Rash—Levothyroxine—hypothyroidism	0.000273	0.00451	CcSEcCtD
Sorafenib—Rash—Dextrothyroxine—hypothyroidism	0.000273	0.00451	CcSEcCtD
Sorafenib—Dermatitis—Dextrothyroxine—hypothyroidism	0.000273	0.0045	CcSEcCtD
Sorafenib—Dermatitis—Levothyroxine—hypothyroidism	0.000273	0.0045	CcSEcCtD
Sorafenib—Constipation—Liotrix—hypothyroidism	0.000272	0.0045	CcSEcCtD
Sorafenib—HIPK3—cerebellum—hypothyroidism	0.000271	0.00292	CbGeAlD
Sorafenib—RET—pituitary gland—hypothyroidism	0.000271	0.00292	CbGeAlD
Sorafenib—Headache—Levothyroxine—hypothyroidism	0.000271	0.00448	CcSEcCtD
Sorafenib—Headache—Dextrothyroxine—hypothyroidism	0.000271	0.00448	CcSEcCtD
Sorafenib—FGFR1—adrenal gland—hypothyroidism	0.000271	0.00291	CbGeAlD
Sorafenib—STK10—heart—hypothyroidism	0.000271	0.00291	CbGeAlD
Sorafenib—FLT1—cardiovascular system—hypothyroidism	0.00027	0.0029	CbGeAlD
Sorafenib—RAF1—cardiovascular system—hypothyroidism	0.000268	0.00289	CbGeAlD
Sorafenib—PDGFRA—heart—hypothyroidism	0.000268	0.00288	CbGeAlD
Sorafenib—FLT4—thyroid gland—hypothyroidism	0.000265	0.00285	CbGeAlD
Sorafenib—BRAF—testis—hypothyroidism	0.000263	0.00283	CbGeAlD
Sorafenib—FGFR1—thyroid gland—hypothyroidism	0.000261	0.00281	CbGeAlD
Sorafenib—Gastrointestinal pain—Liotrix—hypothyroidism	0.00026	0.0043	CcSEcCtD
Sorafenib—TIE1—liver—hypothyroidism	0.00026	0.00279	CbGeAlD
Sorafenib—Nausea—Dextrothyroxine—hypothyroidism	0.000257	0.00425	CcSEcCtD
Sorafenib—Nausea—Levothyroxine—hypothyroidism	0.000257	0.00425	CcSEcCtD
Sorafenib—MAP3K7—adrenal gland—hypothyroidism	0.000256	0.00276	CbGeAlD
Sorafenib—MAP3K7—blood—hypothyroidism	0.000256	0.00276	CbGeAlD
Sorafenib—FLT4—female gonad—hypothyroidism	0.000256	0.00275	CbGeAlD
Sorafenib—STK10—cardiovascular system—hypothyroidism	0.000255	0.00275	CbGeAlD
Sorafenib—TIE1—cerebellum—hypothyroidism	0.000254	0.00273	CbGeAlD
Sorafenib—Urticaria—Liotrix—hypothyroidism	0.000253	0.00418	CcSEcCtD
Sorafenib—PDGFRA—cardiovascular system—hypothyroidism	0.000253	0.00272	CbGeAlD
Sorafenib—FGFR1—female gonad—hypothyroidism	0.000252	0.00272	CbGeAlD
Sorafenib—Abdominal pain—Liotrix—hypothyroidism	0.000252	0.00416	CcSEcCtD
Sorafenib—Body temperature increased—Liotrix—hypothyroidism	0.000252	0.00416	CcSEcCtD
Sorafenib—EPHX2—testis—hypothyroidism	0.000252	0.00271	CbGeAlD
Sorafenib—RALBP1—pituitary gland—hypothyroidism	0.000251	0.0027	CbGeAlD
Sorafenib—MAP2K5—adrenal cortex—hypothyroidism	0.00025	0.00269	CbGeAlD
Sorafenib—KDR—adrenal cortex—hypothyroidism	0.00025	0.00269	CbGeAlD
Sorafenib—FLT3—testis—hypothyroidism	0.00025	0.00269	CbGeAlD
Sorafenib—BRAF—liver—hypothyroidism	0.000249	0.00268	CbGeAlD
Sorafenib—MKNK2—adrenal gland—hypothyroidism	0.000248	0.00267	CbGeAlD
Sorafenib—MKNK2—blood—hypothyroidism	0.000248	0.00267	CbGeAlD
Sorafenib—MAP3K7—thyroid gland—hypothyroidism	0.000247	0.00266	CbGeAlD
Sorafenib—MKNK1—adrenal gland—hypothyroidism	0.000245	0.00264	CbGeAlD
Sorafenib—MKNK1—blood—hypothyroidism	0.000245	0.00264	CbGeAlD
Sorafenib—FLT1—gonad—hypothyroidism	0.000245	0.00263	CbGeAlD
Sorafenib—CSF1R—adrenal cortex—hypothyroidism	0.000244	0.00262	CbGeAlD
Sorafenib—RAF1—gonad—hypothyroidism	0.000243	0.00262	CbGeAlD
Sorafenib—BRAF—cerebellum—hypothyroidism	0.000243	0.00262	CbGeAlD
Sorafenib—RET—adrenal gland—hypothyroidism	0.000242	0.00261	CbGeAlD
Sorafenib—RET—blood—hypothyroidism	0.000242	0.00261	CbGeAlD
Sorafenib—MAP2K5—heart—hypothyroidism	0.000242	0.0026	CbGeAlD
Sorafenib—KDR—heart—hypothyroidism	0.000242	0.0026	CbGeAlD
Sorafenib—MKNK2—thyroid gland—hypothyroidism	0.00024	0.00258	CbGeAlD
Sorafenib—MAP3K7—female gonad—hypothyroidism	0.000239	0.00257	CbGeAlD
Sorafenib—FLT1—pituitary gland—hypothyroidism	0.000239	0.00257	CbGeAlD
Sorafenib—EPHX2—liver—hypothyroidism	0.000238	0.00256	CbGeAlD
Sorafenib—RAF1—pituitary gland—hypothyroidism	0.000237	0.00255	CbGeAlD
Sorafenib—MKNK1—thyroid gland—hypothyroidism	0.000237	0.00255	CbGeAlD
Sorafenib—FLT3—liver—hypothyroidism	0.000236	0.00254	CbGeAlD
Sorafenib—EPHB6—pituitary gland—hypothyroidism	0.000236	0.00254	CbGeAlD
Sorafenib—CSF1R—heart—hypothyroidism	0.000236	0.00254	CbGeAlD
Sorafenib—Hypersensitivity—Liotrix—hypothyroidism	0.000235	0.00387	CcSEcCtD
Sorafenib—RET—thyroid gland—hypothyroidism	0.000234	0.00252	CbGeAlD
Sorafenib—EPHX2—cerebellum—hypothyroidism	0.000232	0.0025	CbGeAlD
Sorafenib—STK10—gonad—hypothyroidism	0.000232	0.00249	CbGeAlD
Sorafenib—MKNK2—female gonad—hypothyroidism	0.000232	0.00249	CbGeAlD
Sorafenib—FLT3—cerebellum—hypothyroidism	0.000231	0.00248	CbGeAlD
Sorafenib—PDGFRA—gonad—hypothyroidism	0.000229	0.00247	CbGeAlD
Sorafenib—MKNK1—female gonad—hypothyroidism	0.000229	0.00246	CbGeAlD
Sorafenib—Asthenia—Liotrix—hypothyroidism	0.000228	0.00377	CcSEcCtD
Sorafenib—MAP2K5—cardiovascular system—hypothyroidism	0.000228	0.00245	CbGeAlD
Sorafenib—KDR—cardiovascular system—hypothyroidism	0.000228	0.00245	CbGeAlD
Sorafenib—FLT4—testis—hypothyroidism	0.000227	0.00244	CbGeAlD
Sorafenib—Pruritus—Liotrix—hypothyroidism	0.000225	0.00372	CcSEcCtD
Sorafenib—RALBP1—adrenal gland—hypothyroidism	0.000224	0.00241	CbGeAlD
Sorafenib—RALBP1—blood—hypothyroidism	0.000224	0.00241	CbGeAlD
Sorafenib—FGFR1—testis—hypothyroidism	0.000224	0.00241	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—hypothyroidism	0.000222	0.00239	CbGeAlD
Sorafenib—Diarrhoea—Liotrix—hypothyroidism	0.000218	0.0036	CcSEcCtD
Sorafenib—UGT1A9—liver—hypothyroidism	0.000218	0.00234	CbGeAlD
Sorafenib—RALBP1—thyroid gland—hypothyroidism	0.000216	0.00233	CbGeAlD
Sorafenib—PDGFRB—adrenal cortex—hypothyroidism	0.000216	0.00233	CbGeAlD
Sorafenib—FLT4—liver—hypothyroidism	0.000215	0.00231	CbGeAlD
Sorafenib—KIT—heart—hypothyroidism	0.000214	0.0023	CbGeAlD
Sorafenib—FLT1—adrenal gland—hypothyroidism	0.000213	0.0023	CbGeAlD
Sorafenib—FLT1—blood—hypothyroidism	0.000213	0.0023	CbGeAlD
Sorafenib—RAF1—adrenal gland—hypothyroidism	0.000212	0.00228	CbGeAlD
Sorafenib—RAF1—blood—hypothyroidism	0.000212	0.00228	CbGeAlD
Sorafenib—MAP3K7—testis—hypothyroidism	0.000212	0.00228	CbGeAlD
Sorafenib—FGFR1—liver—hypothyroidism	0.000212	0.00228	CbGeAlD
Sorafenib—EPHB6—adrenal gland—hypothyroidism	0.000211	0.00227	CbGeAlD
Sorafenib—EPHB6—blood—hypothyroidism	0.000211	0.00227	CbGeAlD
Sorafenib—Dizziness—Liotrix—hypothyroidism	0.00021	0.00348	CcSEcCtD
Sorafenib—RALBP1—female gonad—hypothyroidism	0.000209	0.00225	CbGeAlD
Sorafenib—PDGFRB—heart—hypothyroidism	0.000209	0.00225	CbGeAlD
Sorafenib—FGFR1—cerebellum—hypothyroidism	0.000207	0.00222	CbGeAlD
Sorafenib—FLT1—thyroid gland—hypothyroidism	0.000206	0.00222	CbGeAlD
Sorafenib—MKNK2—testis—hypothyroidism	0.000205	0.00221	CbGeAlD
Sorafenib—RAF1—thyroid gland—hypothyroidism	0.000205	0.0022	CbGeAlD
Sorafenib—EPHB6—thyroid gland—hypothyroidism	0.000203	0.00219	CbGeAlD
Sorafenib—MKNK1—testis—hypothyroidism	0.000203	0.00218	CbGeAlD
Sorafenib—Vomiting—Liotrix—hypothyroidism	0.000202	0.00334	CcSEcCtD
Sorafenib—KIT—cardiovascular system—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—STK10—adrenal gland—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—CSF1R—gonad—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—STK10—blood—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—KDR—pituitary gland—hypothyroidism	0.000202	0.00217	CbGeAlD
Sorafenib—Rash—Liotrix—hypothyroidism	0.000201	0.00331	CcSEcCtD
Sorafenib—Dermatitis—Liotrix—hypothyroidism	0.000201	0.00331	CcSEcCtD
Sorafenib—MAP3K7—liver—hypothyroidism	0.0002	0.00216	CbGeAlD
Sorafenib—RET—testis—hypothyroidism	0.0002	0.00216	CbGeAlD
Sorafenib—PDGFRA—adrenal gland—hypothyroidism	0.0002	0.00215	CbGeAlD
Sorafenib—PDGFRA—blood—hypothyroidism	0.0002	0.00215	CbGeAlD
Sorafenib—Headache—Liotrix—hypothyroidism	0.000199	0.00329	CcSEcCtD
Sorafenib—FLT1—female gonad—hypothyroidism	0.000199	0.00214	CbGeAlD
Sorafenib—RAF1—female gonad—hypothyroidism	0.000198	0.00213	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—hypothyroidism	0.000197	0.00212	CbGeAlD
Sorafenib—CSF1R—pituitary gland—hypothyroidism	0.000197	0.00212	CbGeAlD
Sorafenib—EPHB6—female gonad—hypothyroidism	0.000197	0.00212	CbGeAlD
Sorafenib—MAP3K7—cerebellum—hypothyroidism	0.000196	0.00211	CbGeAlD
Sorafenib—STK10—thyroid gland—hypothyroidism	0.000195	0.0021	CbGeAlD
Sorafenib—MKNK2—liver—hypothyroidism	0.000194	0.00209	CbGeAlD
Sorafenib—PDGFRA—thyroid gland—hypothyroidism	0.000193	0.00208	CbGeAlD
Sorafenib—MKNK1—liver—hypothyroidism	0.000192	0.00206	CbGeAlD
Sorafenib—UGT1A1—blood—hypothyroidism	0.000191	0.00205	CbGeAlD
Sorafenib—MKNK2—cerebellum—hypothyroidism	0.00019	0.00204	CbGeAlD
Sorafenib—Nausea—Liotrix—hypothyroidism	0.000189	0.00312	CcSEcCtD
Sorafenib—STK10—female gonad—hypothyroidism	0.000188	0.00203	CbGeAlD
Sorafenib—MKNK1—cerebellum—hypothyroidism	0.000187	0.00202	CbGeAlD
Sorafenib—PDGFRA—female gonad—hypothyroidism	0.000186	0.00201	CbGeAlD
Sorafenib—RALBP1—testis—hypothyroidism	0.000185	0.002	CbGeAlD
Sorafenib—RET—cerebellum—hypothyroidism	0.000185	0.00199	CbGeAlD
Sorafenib—KIT—gonad—hypothyroidism	0.000183	0.00197	CbGeAlD
Sorafenib—CYP3A7—liver—hypothyroidism	0.000181	0.00195	CbGeAlD
Sorafenib—MAP2K5—adrenal gland—hypothyroidism	0.00018	0.00194	CbGeAlD
Sorafenib—KDR—adrenal gland—hypothyroidism	0.00018	0.00194	CbGeAlD
Sorafenib—KDR—blood—hypothyroidism	0.00018	0.00194	CbGeAlD
Sorafenib—MAP2K5—blood—hypothyroidism	0.00018	0.00194	CbGeAlD
Sorafenib—PDGFRB—gonad—hypothyroidism	0.000179	0.00193	CbGeAlD
Sorafenib—KIT—pituitary gland—hypothyroidism	0.000179	0.00192	CbGeAlD
Sorafenib—FLT1—testis—hypothyroidism	0.000176	0.0019	CbGeAlD
Sorafenib—CSF1R—adrenal gland—hypothyroidism	0.000176	0.00189	CbGeAlD
Sorafenib—CSF1R—blood—hypothyroidism	0.000176	0.00189	CbGeAlD
Sorafenib—RAF1—testis—hypothyroidism	0.000175	0.00189	CbGeAlD
Sorafenib—RALBP1—liver—hypothyroidism	0.000175	0.00189	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—hypothyroidism	0.000175	0.00188	CbGeAlD
Sorafenib—EPHB6—testis—hypothyroidism	0.000174	0.00188	CbGeAlD
Sorafenib—MAP2K5—thyroid gland—hypothyroidism	0.000174	0.00187	CbGeAlD
Sorafenib—KDR—thyroid gland—hypothyroidism	0.000174	0.00187	CbGeAlD
Sorafenib—RALBP1—cerebellum—hypothyroidism	0.000171	0.00184	CbGeAlD
Sorafenib—HTR2B—adrenal cortex—hypothyroidism	0.000171	0.00184	CbGeAlD
Sorafenib—CSF1R—thyroid gland—hypothyroidism	0.00017	0.00183	CbGeAlD
Sorafenib—KDR—female gonad—hypothyroidism	0.000168	0.00181	CbGeAlD
Sorafenib—MAP2K5—female gonad—hypothyroidism	0.000168	0.00181	CbGeAlD
Sorafenib—STK10—testis—hypothyroidism	0.000167	0.0018	CbGeAlD
Sorafenib—FLT1—liver—hypothyroidism	0.000167	0.00179	CbGeAlD
Sorafenib—ABCC4—heart—hypothyroidism	0.000167	0.00179	CbGeAlD
Sorafenib—RAF1—liver—hypothyroidism	0.000166	0.00178	CbGeAlD
Sorafenib—HTR2B—heart—hypothyroidism	0.000166	0.00178	CbGeAlD
Sorafenib—PDGFRA—testis—hypothyroidism	0.000165	0.00178	CbGeAlD
Sorafenib—CSF1R—female gonad—hypothyroidism	0.000164	0.00177	CbGeAlD
Sorafenib—FLT1—cerebellum—hypothyroidism	0.000163	0.00175	CbGeAlD
Sorafenib—RAF1—cerebellum—hypothyroidism	0.000162	0.00174	CbGeAlD
Sorafenib—EPHB6—cerebellum—hypothyroidism	0.000161	0.00173	CbGeAlD
Sorafenib—KIT—adrenal gland—hypothyroidism	0.00016	0.00172	CbGeAlD
Sorafenib—KIT—blood—hypothyroidism	0.00016	0.00172	CbGeAlD
Sorafenib—STK10—liver—hypothyroidism	0.000158	0.0017	CbGeAlD
Sorafenib—PDGFRA—liver—hypothyroidism	0.000156	0.00168	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—hypothyroidism	0.000156	0.00168	CbGeAlD
Sorafenib—PDGFRB—adrenal gland—hypothyroidism	0.000156	0.00168	CbGeAlD
Sorafenib—PDGFRB—blood—hypothyroidism	0.000156	0.00168	CbGeAlD
Sorafenib—STK10—cerebellum—hypothyroidism	0.000154	0.00166	CbGeAlD
Sorafenib—KIT—thyroid gland—hypothyroidism	0.000154	0.00166	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—hypothyroidism	0.000154	0.00166	CbGeAlD
Sorafenib—PDGFRA—cerebellum—hypothyroidism	0.000153	0.00164	CbGeAlD
Sorafenib—PDGFRB—thyroid gland—hypothyroidism	0.000151	0.00162	CbGeAlD
Sorafenib—KDR—testis—hypothyroidism	0.000149	0.0016	CbGeAlD
Sorafenib—MAP2K5—testis—hypothyroidism	0.000149	0.0016	CbGeAlD
Sorafenib—UGT1A1—liver—hypothyroidism	0.000149	0.0016	CbGeAlD
Sorafenib—KIT—female gonad—hypothyroidism	0.000149	0.0016	CbGeAlD
Sorafenib—CSF1R—testis—hypothyroidism	0.000146	0.00157	CbGeAlD
Sorafenib—PDGFRB—female gonad—hypothyroidism	0.000146	0.00157	CbGeAlD
Sorafenib—MAP2K5—liver—hypothyroidism	0.000141	0.00152	CbGeAlD
Sorafenib—KDR—liver—hypothyroidism	0.000141	0.00152	CbGeAlD
Sorafenib—KDR—cerebellum—hypothyroidism	0.000138	0.00148	CbGeAlD
Sorafenib—MAP2K5—cerebellum—hypothyroidism	0.000138	0.00148	CbGeAlD
Sorafenib—CSF1R—liver—hypothyroidism	0.000138	0.00148	CbGeAlD
Sorafenib—CSF1R—cerebellum—hypothyroidism	0.000134	0.00145	CbGeAlD
Sorafenib—KIT—testis—hypothyroidism	0.000132	0.00142	CbGeAlD
Sorafenib—PDGFRB—testis—hypothyroidism	0.000129	0.00139	CbGeAlD
Sorafenib—KIT—liver—hypothyroidism	0.000125	0.00134	CbGeAlD
Sorafenib—ABCC4—adrenal gland—hypothyroidism	0.000124	0.00134	CbGeAlD
Sorafenib—ABCC4—blood—hypothyroidism	0.000124	0.00134	CbGeAlD
Sorafenib—HTR2B—adrenal gland—hypothyroidism	0.000124	0.00133	CbGeAlD
Sorafenib—HTR2B—blood—hypothyroidism	0.000124	0.00133	CbGeAlD
Sorafenib—KIT—cerebellum—hypothyroidism	0.000122	0.00131	CbGeAlD
Sorafenib—PDGFRB—liver—hypothyroidism	0.000122	0.00131	CbGeAlD
Sorafenib—ABCG2—adrenal cortex—hypothyroidism	0.000122	0.00131	CbGeAlD
Sorafenib—ABCC2—adrenal gland—hypothyroidism	0.00012	0.00129	CbGeAlD
Sorafenib—ABCC2—blood—hypothyroidism	0.00012	0.00129	CbGeAlD
Sorafenib—ABCC4—thyroid gland—hypothyroidism	0.00012	0.00129	CbGeAlD
Sorafenib—HTR2B—thyroid gland—hypothyroidism	0.000119	0.00128	CbGeAlD
Sorafenib—PDGFRB—cerebellum—hypothyroidism	0.000119	0.00128	CbGeAlD
Sorafenib—ABCG2—heart—hypothyroidism	0.000118	0.00126	CbGeAlD
Sorafenib—ABCC4—female gonad—hypothyroidism	0.000116	0.00125	CbGeAlD
Sorafenib—CYP2B6—adrenal cortex—hypothyroidism	0.000112	0.00121	CbGeAlD
Sorafenib—CYP2B6—heart—hypothyroidism	0.000108	0.00117	CbGeAlD
Sorafenib—CYP2C9—heart—hypothyroidism	0.000107	0.00116	CbGeAlD
Sorafenib—CYP2C19—blood—hypothyroidism	0.000103	0.00111	CbGeAlD
Sorafenib—ABCC4—testis—hypothyroidism	0.000103	0.00111	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—hypothyroidism	0.000102	0.0011	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—hypothyroidism	0.000101	0.00109	CbGeAlD
Sorafenib—CYP2C8—pituitary gland—hypothyroidism	0.000101	0.00109	CbGeAlD
Sorafenib—ABCC2—testis—hypothyroidism	9.95e-05	0.00107	CbGeAlD
Sorafenib—ABCG2—pituitary gland—hypothyroidism	9.82e-05	0.00106	CbGeAlD
Sorafenib—ABCC4—liver—hypothyroidism	9.72e-05	0.00105	CbGeAlD
Sorafenib—ABCC2—liver—hypothyroidism	9.41e-05	0.00101	CbGeAlD
Sorafenib—CYP2B6—gonad—hypothyroidism	9.29e-05	0.000999	CbGeAlD
Sorafenib—CYP2C8—blood—hypothyroidism	9.02e-05	0.000971	CbGeAlD
Sorafenib—ABCG2—adrenal gland—hypothyroidism	8.77e-05	0.000944	CbGeAlD
Sorafenib—ABCG2—blood—hypothyroidism	8.77e-05	0.000944	CbGeAlD
Sorafenib—ABCG2—thyroid gland—hypothyroidism	8.47e-05	0.000911	CbGeAlD
Sorafenib—CYP1A2—blood—hypothyroidism	8.44e-05	0.000908	CbGeAlD
Sorafenib—ABCG2—female gonad—hypothyroidism	8.18e-05	0.00088	CbGeAlD
Sorafenib—CYP1A2—thyroid gland—hypothyroidism	8.15e-05	0.000877	CbGeAlD
Sorafenib—CYP3A5—blood—hypothyroidism	8.14e-05	0.000876	CbGeAlD
Sorafenib—CYP2B6—adrenal gland—hypothyroidism	8.09e-05	0.000871	CbGeAlD
Sorafenib—CYP2B6—blood—hypothyroidism	8.09e-05	0.000871	CbGeAlD
Sorafenib—CYP2C19—liver—hypothyroidism	8.08e-05	0.00087	CbGeAlD
Sorafenib—CYP2C9—blood—hypothyroidism	8.01e-05	0.000862	CbGeAlD
Sorafenib—CYP3A5—female gonad—hypothyroidism	7.59e-05	0.000817	CbGeAlD
Sorafenib—CYP2C8—testis—hypothyroidism	7.46e-05	0.000803	CbGeAlD
Sorafenib—ABCG2—testis—hypothyroidism	7.26e-05	0.000781	CbGeAlD
Sorafenib—CYP2C8—liver—hypothyroidism	7.05e-05	0.000759	CbGeAlD
Sorafenib—ABCG2—liver—hypothyroidism	6.86e-05	0.000738	CbGeAlD
Sorafenib—ABCG2—cerebellum—hypothyroidism	6.7e-05	0.000721	CbGeAlD
Sorafenib—CYP2B6—testis—hypothyroidism	6.69e-05	0.00072	CbGeAlD
Sorafenib—CYP1A2—liver—hypothyroidism	6.6e-05	0.00071	CbGeAlD
Sorafenib—CYP3A5—liver—hypothyroidism	6.37e-05	0.000685	CbGeAlD
Sorafenib—CYP2B6—liver—hypothyroidism	6.33e-05	0.000681	CbGeAlD
Sorafenib—CYP2C9—liver—hypothyroidism	6.27e-05	0.000674	CbGeAlD
Sorafenib—CYP3A4—blood—hypothyroidism	6.11e-05	0.000657	CbGeAlD
Sorafenib—CYP2D6—blood—hypothyroidism	6.01e-05	0.000647	CbGeAlD
Sorafenib—ABCB1—adrenal cortex—hypothyroidism	5.99e-05	0.000645	CbGeAlD
Sorafenib—ABCB1—heart—hypothyroidism	5.8e-05	0.000624	CbGeAlD
Sorafenib—CYP2D6—female gonad—hypothyroidism	5.61e-05	0.000603	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—hypothyroidism	5.47e-05	0.000589	CbGeAlD
Sorafenib—CYP2D6—testis—hypothyroidism	4.97e-05	0.000535	CbGeAlD
Sorafenib—ABCB1—gonad—hypothyroidism	4.96e-05	0.000534	CbGeAlD
Sorafenib—ABCB1—pituitary gland—hypothyroidism	4.84e-05	0.000521	CbGeAlD
Sorafenib—CYP3A4—liver—hypothyroidism	4.78e-05	0.000514	CbGeAlD
Sorafenib—CYP2D6—liver—hypothyroidism	4.7e-05	0.000506	CbGeAlD
Sorafenib—CYP2D6—cerebellum—hypothyroidism	4.59e-05	0.000494	CbGeAlD
Sorafenib—ABCB1—adrenal gland—hypothyroidism	4.33e-05	0.000466	CbGeAlD
Sorafenib—ABCB1—blood—hypothyroidism	4.33e-05	0.000465	CbGeAlD
Sorafenib—ABCB1—thyroid gland—hypothyroidism	4.17e-05	0.000449	CbGeAlD
Sorafenib—ABCB1—female gonad—hypothyroidism	4.03e-05	0.000434	CbGeAlD
Sorafenib—ABCB1—testis—hypothyroidism	3.58e-05	0.000385	CbGeAlD
Sorafenib—ABCB1—liver—hypothyroidism	3.38e-05	0.000364	CbGeAlD
Sorafenib—ABCB1—cerebellum—hypothyroidism	3.3e-05	0.000356	CbGeAlD
Sorafenib—CYP2C19—Metabolism—IYD—hypothyroidism	1.71e-05	0.000382	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—VAV3—hypothyroidism	1.71e-05	0.000382	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SH2B3—hypothyroidism	1.7e-05	0.00038	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—IYD—hypothyroidism	1.67e-05	0.000373	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SH2B3—hypothyroidism	1.66e-05	0.00037	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—AVP—hypothyroidism	1.66e-05	0.000369	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—AVP—hypothyroidism	1.65e-05	0.000368	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AVP—hypothyroidism	1.65e-05	0.000368	CbGpPWpGaD
Sorafenib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	1.64e-05	0.000367	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—PRL—hypothyroidism	1.64e-05	0.000365	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ATP5O—hypothyroidism	1.63e-05	0.000364	CbGpPWpGaD
Sorafenib—CYP2C8—Biological oxidations—POMC—hypothyroidism	1.63e-05	0.000363	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TRH—hypothyroidism	1.62e-05	0.000361	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TRH—hypothyroidism	1.62e-05	0.000361	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	1.61e-05	0.000358	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TSHB—hypothyroidism	1.6e-05	0.000358	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TSHR—hypothyroidism	1.6e-05	0.000358	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TSHB—hypothyroidism	1.6e-05	0.000357	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TSHR—hypothyroidism	1.6e-05	0.000357	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CLTC—hypothyroidism	1.6e-05	0.000356	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TSHR—hypothyroidism	1.59e-05	0.000354	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TSHB—hypothyroidism	1.59e-05	0.000354	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—IYD—hypothyroidism	1.57e-05	0.000351	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—IYD—hypothyroidism	1.56e-05	0.000348	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TRH—hypothyroidism	1.54e-05	0.000343	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TPO—hypothyroidism	1.53e-05	0.000342	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TRH—hypothyroidism	1.53e-05	0.000342	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CLTC—hypothyroidism	1.52e-05	0.00034	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—POMC—hypothyroidism	1.52e-05	0.000338	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—VAV3—hypothyroidism	1.51e-05	0.000338	CbGpPWpGaD
Sorafenib—BRAF—Disease—PRL—hypothyroidism	1.5e-05	0.000334	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—POMC—hypothyroidism	1.49e-05	0.000333	CbGpPWpGaD
Sorafenib—KIT—Immune System—PRL—hypothyroidism	1.48e-05	0.000329	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PRL—hypothyroidism	1.48e-05	0.000329	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—POMC—hypothyroidism	1.47e-05	0.000328	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ATP5O—hypothyroidism	1.46e-05	0.000325	CbGpPWpGaD
Sorafenib—CYP2C19—Biological oxidations—POMC—hypothyroidism	1.45e-05	0.000324	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—IGF1—hypothyroidism	1.45e-05	0.000323	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TSHB—hypothyroidism	1.44e-05	0.000322	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TSHB—hypothyroidism	1.44e-05	0.000322	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TSHR—hypothyroidism	1.44e-05	0.000322	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TSHR—hypothyroidism	1.44e-05	0.000322	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	1.44e-05	0.000321	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IGF1—hypothyroidism	1.44e-05	0.00032	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SH2B3—hypothyroidism	1.43e-05	0.000318	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CLTC—hypothyroidism	1.42e-05	0.000318	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ATP5O—hypothyroidism	1.42e-05	0.000317	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.42e-05	0.000317	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SH2B3—hypothyroidism	1.41e-05	0.000315	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IGF1—hypothyroidism	1.41e-05	0.000315	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PRL—hypothyroidism	1.4e-05	0.000313	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PRL—hypothyroidism	1.4e-05	0.000312	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TRH—hypothyroidism	1.38e-05	0.000308	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TSHB—hypothyroidism	1.37e-05	0.000306	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TSHR—hypothyroidism	1.37e-05	0.000306	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TPO—hypothyroidism	1.37e-05	0.000305	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TSHB—hypothyroidism	1.37e-05	0.000305	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TSHR—hypothyroidism	1.37e-05	0.000305	CbGpPWpGaD
Sorafenib—KIT—Immune System—VAV3—hypothyroidism	1.37e-05	0.000305	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—VAV3—hypothyroidism	1.37e-05	0.000305	CbGpPWpGaD
Sorafenib—KIT—Disease—PRL—hypothyroidism	1.36e-05	0.000304	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—TSHB—hypothyroidism	1.35e-05	0.000301	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—TSHB—hypothyroidism	1.35e-05	0.000301	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ATP5O—hypothyroidism	1.34e-05	0.000299	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—VAV3—hypothyroidism	1.34e-05	0.000299	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TPO—hypothyroidism	1.34e-05	0.000298	CbGpPWpGaD
Sorafenib—CYP2D6—Biological oxidations—POMC—hypothyroidism	1.33e-05	0.000298	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—IYD—hypothyroidism	1.33e-05	0.000298	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ATP5O—hypothyroidism	1.33e-05	0.000296	CbGpPWpGaD
Sorafenib—CYP2C9—Biological oxidations—POMC—hypothyroidism	1.32e-05	0.000295	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TRH—hypothyroidism	1.32e-05	0.000294	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—VAV3—hypothyroidism	1.3e-05	0.000289	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PRL—hypothyroidism	1.29e-05	0.000289	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—VAV3—hypothyroidism	1.29e-05	0.000288	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PRL—hypothyroidism	1.29e-05	0.000288	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AVP—hypothyroidism	1.29e-05	0.000288	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SH2B3—hypothyroidism	1.29e-05	0.000287	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SH2B3—hypothyroidism	1.29e-05	0.000287	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.27e-05	0.000283	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PRL—hypothyroidism	1.26e-05	0.000282	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TPO—hypothyroidism	1.26e-05	0.000281	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PRL—hypothyroidism	1.26e-05	0.000281	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	1.25e-05	0.00028	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TPO—hypothyroidism	1.25e-05	0.000278	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TSHB—hypothyroidism	1.23e-05	0.000275	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TRH—hypothyroidism	1.23e-05	0.000275	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TSHR—hypothyroidism	1.23e-05	0.000275	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PRL—hypothyroidism	1.23e-05	0.000275	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CLTC—hypothyroidism	1.23e-05	0.000274	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—POMC—hypothyroidism	1.22e-05	0.000273	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SH2B3—hypothyroidism	1.22e-05	0.000272	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—IGF1—hypothyroidism	1.22e-05	0.000272	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SH2B3—hypothyroidism	1.22e-05	0.000272	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—POMC—hypothyroidism	1.22e-05	0.000271	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—VAV3—hypothyroidism	1.22e-05	0.000271	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3C2A—hypothyroidism	1.2e-05	0.000268	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3C2A—hypothyroidism	1.2e-05	0.000268	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.19e-05	0.000265	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TSHB—hypothyroidism	1.17e-05	0.000262	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TSHR—hypothyroidism	1.17e-05	0.000262	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AVP—hypothyroidism	1.17e-05	0.000261	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IGF1—hypothyroidism	1.17e-05	0.000261	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VAV3—hypothyroidism	1.17e-05	0.000261	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—VAV3—hypothyroidism	1.16e-05	0.00026	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PRL—hypothyroidism	1.16e-05	0.000259	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.16e-05	0.000258	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—TSHB—hypothyroidism	1.14e-05	0.000255	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VAV3—hypothyroidism	1.14e-05	0.000254	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—VAV3—hypothyroidism	1.14e-05	0.000253	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ATP5O—hypothyroidism	1.13e-05	0.000253	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—TSHB—hypothyroidism	1.13e-05	0.000253	CbGpPWpGaD
Sorafenib—CYP1A2—Biological oxidations—POMC—hypothyroidism	1.13e-05	0.000252	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AVP—hypothyroidism	1.13e-05	0.000251	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PRL—hypothyroidism	1.12e-05	0.00025	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SH2B3—hypothyroidism	1.1e-05	0.000245	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TSHB—hypothyroidism	1.1e-05	0.000245	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AVP—hypothyroidism	1.1e-05	0.000245	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TSHR—hypothyroidism	1.1e-05	0.000245	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—POMC—hypothyroidism	1.1e-05	0.000244	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AVP—hypothyroidism	1.09e-05	0.000244	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—VAV3—hypothyroidism	1.08e-05	0.000241	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TPO—hypothyroidism	1.07e-05	0.000238	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TRH—hypothyroidism	1.06e-05	0.000237	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PRL—hypothyroidism	1.06e-05	0.000236	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IGF1—hypothyroidism	1.05e-05	0.000235	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PRL—hypothyroidism	1.05e-05	0.000234	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SH2B3—hypothyroidism	1.05e-05	0.000233	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AVP—hypothyroidism	1.04e-05	0.000232	CbGpPWpGaD
Sorafenib—RAF1—Immune System—VAV3—hypothyroidism	1.04e-05	0.000232	CbGpPWpGaD
Sorafenib—RAF1—Disease—PRL—hypothyroidism	1.04e-05	0.000231	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—IYD—hypothyroidism	1.03e-05	0.00023	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3C2A—hypothyroidism	1.02e-05	0.000228	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3C2A—hypothyroidism	1.01e-05	0.000226	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—SLC5A5—hypothyroidism	1.01e-05	0.000225	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—SLC5A5—hypothyroidism	1.01e-05	0.000225	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	9.89e-06	0.000221	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	9.88e-06	0.000221	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—VAV3—hypothyroidism	9.8e-06	0.000219	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VAV3—hypothyroidism	9.79e-06	0.000218	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SH2B3—hypothyroidism	9.78e-06	0.000218	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VAV3—hypothyroidism	9.7e-06	0.000216	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PRL—hypothyroidism	9.54e-06	0.000213	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PRL—hypothyroidism	9.54e-06	0.000213	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSHB—hypothyroidism	9.47e-06	0.000211	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSHR—hypothyroidism	9.47e-06	0.000211	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AVP—hypothyroidism	9.45e-06	0.000211	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AVP—hypothyroidism	9.43e-06	0.00021	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AVP—hypothyroidism	9.34e-06	0.000208	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PRL—hypothyroidism	9.06e-06	0.000202	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PRL—hypothyroidism	9.03e-06	0.000202	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VAV3—hypothyroidism	8.83e-06	0.000197	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VAV3—hypothyroidism	8.83e-06	0.000197	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ATP5O—hypothyroidism	8.76e-06	0.000195	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—POMC—hypothyroidism	8.73e-06	0.000195	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—POMC—hypothyroidism	8.57e-06	0.000191	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—SLC5A5—hypothyroidism	8.56e-06	0.000191	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AVP—hypothyroidism	8.5e-06	0.00019	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AVP—hypothyroidism	8.5e-06	0.00019	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—SLC5A5—hypothyroidism	8.49e-06	0.000189	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SH2B3—hypothyroidism	8.44e-06	0.000188	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TSHB—hypothyroidism	8.39e-06	0.000187	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VAV3—hypothyroidism	8.38e-06	0.000187	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VAV3—hypothyroidism	8.36e-06	0.000186	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TPO—hypothyroidism	8.23e-06	0.000184	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TSHB—hypothyroidism	8.2e-06	0.000183	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PRL—hypothyroidism	8.14e-06	0.000182	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AVP—hypothyroidism	8.07e-06	0.00018	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AVP—hypothyroidism	8.05e-06	0.00018	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	7.78e-06	0.000174	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—POMC—hypothyroidism	7.78e-06	0.000174	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PRL—hypothyroidism	7.76e-06	0.000173	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VAV3—hypothyroidism	7.53e-06	0.000168	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—POMC—hypothyroidism	7.48e-06	0.000167	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3C2A—hypothyroidism	7.47e-06	0.000167	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	7.31e-06	0.000163	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—POMC—hypothyroidism	7.29e-06	0.000163	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—POMC—hypothyroidism	7.27e-06	0.000162	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AVP—hypothyroidism	7.25e-06	0.000162	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PRL—hypothyroidism	7.25e-06	0.000162	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IGF1—hypothyroidism	7.19e-06	0.000161	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VAV3—hypothyroidism	7.18e-06	0.00016	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TSHB—hypothyroidism	7.1e-06	0.000158	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IGF1—hypothyroidism	7.01e-06	0.000156	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AVP—hypothyroidism	6.92e-06	0.000154	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—POMC—hypothyroidism	6.91e-06	0.000154	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VAV3—hypothyroidism	6.71e-06	0.00015	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AVP—hypothyroidism	6.46e-06	0.000144	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TSHB—hypothyroidism	6.34e-06	0.000141	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	6.33e-06	0.000141	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SLC5A5—hypothyroidism	6.28e-06	0.00014	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—POMC—hypothyroidism	6.28e-06	0.00014	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—POMC—hypothyroidism	6.27e-06	0.00014	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PRL—hypothyroidism	6.26e-06	0.00014	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	6.24e-06	0.000139	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—POMC—hypothyroidism	6.21e-06	0.000139	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TSHB—hypothyroidism	6.19e-06	0.000138	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC5A5—hypothyroidism	6.14e-06	0.000137	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IGF1—hypothyroidism	6.03e-06	0.000135	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IGF1—hypothyroidism	5.97e-06	0.000133	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TSHB—hypothyroidism	5.83e-06	0.00013	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VAV3—hypothyroidism	5.79e-06	0.000129	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TSHB—hypothyroidism	5.78e-06	0.000129	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—POMC—hypothyroidism	5.65e-06	0.000126	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—POMC—hypothyroidism	5.65e-06	0.000126	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	5.65e-06	0.000126	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AVP—hypothyroidism	5.58e-06	0.000125	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.57e-06	0.000124	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	5.51e-06	0.000123	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF1—hypothyroidism	5.44e-06	0.000121	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF1—hypothyroidism	5.44e-06	0.000121	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—POMC—hypothyroidism	5.36e-06	0.00012	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—POMC—hypothyroidism	5.35e-06	0.000119	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC5A5—hypothyroidism	5.32e-06	0.000119	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—POMC—hypothyroidism	5.28e-06	0.000118	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—POMC—hypothyroidism	5.28e-06	0.000118	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	5.2e-06	0.000116	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF1—hypothyroidism	5.16e-06	0.000115	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	5.15e-06	0.000115	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF1—hypothyroidism	5.15e-06	0.000115	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.08e-06	0.000113	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TSHB—hypothyroidism	4.94e-06	0.00011	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—hypothyroidism	4.82e-06	0.000108	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC5A5—hypothyroidism	4.74e-06	0.000106	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF1—hypothyroidism	4.64e-06	0.000103	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC5A5—hypothyroidism	4.63e-06	0.000103	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—hypothyroidism	4.6e-06	0.000103	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—hypothyroidism	4.48e-06	0.0001	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—hypothyroidism	4.44e-06	9.91e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF1—hypothyroidism	4.42e-06	9.86e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	4.4e-06	9.82e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC5A5—hypothyroidism	4.36e-06	9.74e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	4.34e-06	9.69e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC5A5—hypothyroidism	4.33e-06	9.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—hypothyroidism	4.3e-06	9.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—hypothyroidism	4.13e-06	9.22e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TSHB—hypothyroidism	3.81e-06	8.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—hypothyroidism	3.71e-06	8.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC5A5—hypothyroidism	3.7e-06	8.25e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—hypothyroidism	3.57e-06	7.96e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	3.4e-06	7.58e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—hypothyroidism	3.28e-06	7.33e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—hypothyroidism	3.21e-06	7.16e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	2.85e-06	6.37e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—hypothyroidism	2.78e-06	6.2e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—hypothyroidism	2.48e-06	5.54e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—hypothyroidism	2.42e-06	5.41e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—hypothyroidism	2.28e-06	5.09e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—hypothyroidism	2.26e-06	5.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—hypothyroidism	1.93e-06	4.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—hypothyroidism	1.49e-06	3.33e-05	CbGpPWpGaD
